Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion

Industry Insight by 2FIRSTS, edited by Sophia
Apr.08.2024
Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion
EVO NXT Interview: 2FIRSTS discussed nicotine pouch market trends with NNPA.EU leaders Jonas Lundqvist and Rebert Casinge.

Recently, at the EVO NXT tobacco exhibition in Spain, 2FIRSTS engaged in a deep discussion with Jonas Lundqvist, CEO of the Nordic Nicotine Pouches Alliance (NNPA.EU), and Robert Casinge, Editor-in-Chief of pouchforum.eu, about the trends, regulations, and future development of the nicotine pouch market. The NNPA.EU, headquartered in Brussels, has been studying the trends in oral tobacco consumption for 20 years.

 

Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion
Jonas Lundqvist (left) and Robert Casinge (right) | Image source: 2FIRSTS

 

EU Market is Experiencing Robust Growth

 

According to data, the number of nicotine pouch users in the European Union is steadily increasing, reaching 2.6 million. The adult usage rate is 0.7%, with an annual growth rate of 7%. This trend indicates a continued interest and acceptance among consumers for this product. Nicotine pouches overlap with traditional cigarettes, especially among users seeking reduced harm alternatives.

 

In terms of market, the European Union has over 90 nicotine pouch brands, with main producing countries including Sweden, Denmark, Hungary, Poland, Italy, and the Czech Republic. The majority of sales channels are offline, accounting for 68%, while online sales make up 32%. Forecasts indicate that by 2027, the nicotine pouch market value is expected to reach 15-16 billion euros, potentially even reaching 21 billion euros, provided that the policy environment remains favorable.

 

Regulatory Challenges to be Addressed

 

However, the nicotine pouch market also faces regulatory challenges. While most European Union countries consider it a general consumer product, there are still some countries that classify it as a tobacco product or a medicine/food product.

 

For example, the number of snus (nicotine pouch) users in Sweden is similar to the EU average, but the proportion of cigarette smokers is lower (5-6%), especially among young people, leading the World Health Organization to consider Sweden a smoke-free country. However, 9 EU countries classify nicotine pouch as a tobacco-related product, 4 as a medicine/food, and most countries (14) consider it a general consumer product.

 

As the host country of this exhibition, Spain's policies are unclear, while Bulgaria and Greece have specific tax policies on nicotine pouches.

 

Although the European Union has not yet established specific regulations, signs indicate that it may include it in the Tobacco Products Directive in the future. Of particular note is that Nordic governments are actively strengthening regulation of nicotine pouches, with Finland recently legalizing them as smoking cessation aids and imposing restrictions on sales to curb illegal smuggling and sales.

 

Public Attitudes Divide, Caution Needed in Product Innovation

 

There is a certain amount of disagreement in public attitudes. A public opinion consultation by the European Commission showed that the public and health organizations generally support nicotine pouches as a smoking cessation tool, but regulators are cautious about their health impacts. For example, it is deemed acceptable for each nicotine pouch to contain 20mg of nicotine, and products with high nicotine content should not exceed 50mg.

 

The popularity of nicotine pouches is mainly due to their simple and convenient nature - no charging or e-liquid is required, making them easy to carry and suitable for replacing traditional cigarettes. However, the issues of product flavor and market demand should not be overlooked. Manufacturers need to be cautious of flavors that may appeal to children, and strengthen the control and balance of chemical ingredients.

 

Therefore, although the nicotine pouch market is showing strong momentum in growth, regulatory disputes and public concerns are still ongoing. The key to future development lies in changes in the policy environment and the improvement of market innovation capabilities.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12